Literature DB >> 1150040

Kinetics of cholesterol and bile acids in patients with cholesterol cholelithiasis.

G W Hepner, S H Quarfordt.   

Abstract

The kinetics of cholesterol and bile acid was determined from a 10-week analysis of the biliary lipids after a single injection of labeled cholesterol in parallel with a conventional 1-week study of primary bile acid kinetics. Six healthy controls and 6 patients with cholesterol cholelithiasis were studied. Two of the 6 cholesterol cholelithiasis subjects had kinetic values that were very similar to the controls and the other 4 were significantly different. These 4 patients had significantly smaller primary bile acid pools and significantly lower fractional conversions of cholesterol to both primary bile acids, with concomitantly lower bile acid flux. No significant differences were obtained for the size of the rapidly miscible cholesterol pool, the fractional rate of loss and flux of biliary neutral sterol, and the fractional turnover of the primary bile acid pools. These kinetic data support the hypothesis that in some patients with cholesterol cholelithiasis there is defective conversion of cholesterol to bile acids.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1150040

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  3 in total

1.  The effect of phenobarbital on biliary lipid metabolism and hepatic microsomal drug metabolism in patients with cholesterol cholelithiasis.

Authors:  G W Hepner
Journal:  Am J Dig Dis       Date:  1976-05

2.  The influence of chenodeoxycholic acid on cholesterol and bile acid turnover in humans with cholelithiasis.

Authors:  S H Quarfordt; R Jain; M R Greenfield
Journal:  Lipids       Date:  1983-02       Impact factor: 1.880

Review 3.  The use of stable and radioactive sterol tracers as a tool to investigate cholesterol degradation to bile acids in humans in vivo.

Authors:  Marco Bertolotti; Andrea Crosignani; Marina Del Puppo
Journal:  Molecules       Date:  2012-02-16       Impact factor: 4.411

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.